Showing 101-110 of 3189 results for "".
- Review and Analysis: Triple-agent Fixed-dose Combo Tops Acne Treatmentshttps://practicaldermatology.com/news/comparative-effectiveness-moderate-severe-acne-treatments-systematic-review-and-network-meta-analysis/2462740/A topical triple-agent fixed-dose combination (FDC) was shown to be efficacious in comparison to other acne agents, according to result
- LEO Foundation Plans to Double Philanthropic Grants for Skin Diseaseshttps://practicaldermatology.com/news/leo-foundation-plans-double-philanthropic-grants-skin-diseases/2462483/Reporting a successful year in 2023, the LEO Foundation has announced its goals and aspirations out to 2030, including the awarding of a prestigious 5 million Danish kroner prize to a distinguished researcher in Denmark contributing to skin research. The Foundation plans to double its phi
- Kymera Update: First Patient Dosed in Phase 2 AD Clinical Trial of KT-474, a First-in-Class Investigational IRAK4 Degraderhttps://practicaldermatology.com/news/kymera-update-first-patient-dosed-in-phase-2-ad-clinical-trial-of-kt-474-a-first-in-class-investigational-irak4-degrader/2462177/The first patient has been dosed in the Phase 2 clinical trial (ADVANTA) evaluating KT-474 in AD, generating a $15 million milestone payment under its collaboration with Sanofi. KT-474 is an oral IRAK4 degrader, in development for the treatment of IL-1R/TLR-driven complex inflamma
- Dial Gives Back to Teachers With DonorsChoose, TeacherListshttps://practicaldermatology.com/news/dial-gives-back-to-teachers-with-donorschoose-teacherlists/2462170/For the third consecutive year, Dial is partnering with DonorsChoose, an education-focused nonprofit that supports public sc
- FDA Accepts Arcutis’ sNDA for Roflumilast Cream 0.15% for Treatment of AD in Adults and Children Down to Age 6https://practicaldermatology.com/news/fda-accepts-arcutis-snda-for-roflumilast-cream-015-for-treatment-of-ad-in-adults-and-children-down-to-age-6/2462159/The U.S. Food and Drug Administration (FDA) has accepted Arcutis’ supplemental new drug application (sNDA) for roflumilast cream 0.15% for the treatment of atopic dermatitis (AD) in adults and children down to age 6. Roflumilast cream is a once-daily, steroid
- Man Vs. Machine: AI May Be as Reliable as Doctors for Diagnosing Skin Cancerhttps://practicaldermatology.com/news/man-vs-machine-ai-may-be-as-reliable-as-doctors-for-diagnosing-skin-cancer/2462088/Skin cancer diagnoses using artificial intelligence (AI) are as reliable as those made by medical experts, but doctors are clearly superior when it came to treatment decisions. These are the main takeaways from research looking at AI applications under realisti
- Dove Gives Back With the Dove Nature Regeneration Projecthttps://practicaldermatology.com/news/dove-gives-back-with-the-dove-nature-regeneration-project/2461947/Dove is introducing their Nature Regeneration Project, a new initiative to protect nature and tackle climate change. In partnership with the Rimba Collective, Dove will help protect and restore 123,000 acres of rainforest in Southeast Asia –an area 8x the size of&n
- First Patient Dosed in Phase 1/2a Trial of AGLE-102 to Treat Severe Second-degree Burnshttps://practicaldermatology.com/news/first-patient-dosed-in-phase-12a-trial-of-agle-102-to-treat-severe-second-degree-burns/2461938/The first patient has been dosed in Aegle Therapeutics Corp.’s Phase 1/2a clinical trial of AGLE-102 for the treatment of severe second-degree burns. AGLE-102 is an investigational product comprised of native extracellular vesicles isolated from allogeneic stem cel
- VitaSea Gives Back: Skincare Brand to Donate 100% of their Proceeds from Online Sales to the Maui Strong Fund through September 2023https://practicaldermatology.com/news/vitasea-gives-back-skincare-brand-to-donate-100-of-their-proceeds-from-online-sales-to-the-maui-strong-fund-through-september-2023/2461931/VitaSea is donating 100% of their proceeds from online sales to the
- First AD Patient Dosed in Lynk Pharmaceuticals' Phase Ib Clinical Study of Topical JAK Inhibitorhttps://practicaldermatology.com/news/first-ad-patient-dosed-in-lynk-pharmaceuticals-phase-ib-clinical-study-of-topical-jak-inhibitor/2461881/The first atopic dermatitis (AD) patient has been dosed in a Phase Ib clinical trial of LNK01004, Lynk Pharmaceuticals Co., Ltd. The trial was designed to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of LNK01004 ointment in Chinese patient